# ClearNote Health multi-cancer epigenomics study

Source: https://onco.cc/trials/clearnote-multi-cancer-epigenomics/  
OnCo record `clearnote-multi-cancer-epigenomics` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ClearNote Health's long-running study collecting blood from people with cancer to build its multi-cancer detection test.

## Summary

ClearNote Health multi-cancer epigenomics study (NCT03869814) is an observational study sponsored by ClearNote Health. It aims to employ genomic, epigenomic and proteomic methods to detect a cancer signal in the blood of people with solid tumours.

The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 20,000 participants, a start on 5 April 2018 and primary completion expected on 13 June 2029.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-29
- Registry id: NCT03869814
- Phase: observational
- Setting: People with solid tumours and controls in the United States, giving blood for genomic, epigenomic and protein analysis
- Sponsor: ClearNote Health
- Enrolled: 20000

## Sources

- ClinicalTrials.gov NCT03869814: https://clinicaltrials.gov/study/NCT03869814

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [Avantect Multi-Cancer Detection Test](https://onco.cc/drugs/avantect-mcd/)
- companies: [ClearNote Health](https://onco.cc/companies/clearnote-health/)

---
JSON: https://onco.cc/api/v1/entities/clearnote-multi-cancer-epigenomics.json